On Aug. 8, Sesen Bio (SESN), reported Q2 earnings and updates from the Phase 3 VISTA trial for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC). Following the VISTA trial update, the stock price rose by more than 5% in after-hours trading, but the subsequent trading day yanked it back down. In this article, we intend to review recent clinical findings of the VISTA trial and discuss what shareholders can expect going forward.
Brief Background
Sesen Bio (SESN) is a late-stage clinical biotechnology company headquartered in Cambridge, Mass., that concentrates on developing targeted